Compare Freshworks Inc (FRSH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs GeneDx Holdings Corp — how do they compare? Freshworks Inc trades at $13.92 (market cap $3.56B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Freshworks Inc is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and GeneDx Holdings Corp for 19 Days on average.
| FRSH | WGS | |
|---|---|---|
Market Cap | $3.56B | $2.02B |
Volume | 9,066,454 | 734,640 |
Sector | Technology | Health |
52-Week High | $13.92 | $167.51 |
52-Week Low | $6.88 | $34.51 |
Typical Hold Time | 39 Days | 19 Days |
Enterprise Value | $2.93B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.64, up 0.29% on the day, with a bullish technical signal and strong fundamental momentum. The company achieved its first quarter of GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, supported by a high gross margin of 84.96%. Analyst sentiment is evenly split between Buy and Hold, with a consensus price target of $14.60.
The outlook for FRSH is positive, driven by sustained revenue growth, improving profitability, and strategic focus on AI and enterprise solutions. Key risks include competitive pressures in the SaaS sector and execution challenges in maintaining growth momentum. The stock presents an opportunity for upside relative to the consensus target, but investors should monitor quarterly execution against elevated expectations.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
